Eric HALIOUA
CEO
PDC LINE PHARMA
LIEGE, Liège, Belgium
Serial entrepreneur that combines strong strategic, technological and managerial experience with proven track record of deal-making and fund-raising.
About me
Serial entrepreneur that combines strong strategic, technological and managerial experience with proven track record of deal-making and fund-raising. During his career he achieved together with his different teams to bring four drug candidates from research to the clinics (up to phase IIb). Overall, Eric has raised as of now a total of more than €170 million from VCs and strategic partners in Europe, USA, Japan and Korea and have had numerous successes in the sale and initial public offering of biotechnology companies. He is CEO of the biotechnology company PDC*line Pharma and board member of Essenscia(Bio.be). Eric is co-founder of four biotechnology companies called Myosix (bought by Genzyme mid-2002), Murigenetics, HairClone and Digital Orthopaedics. He is co-Inventor of the first GMP approved mobile manufacturing unit for cell therapy. Eric worked for 12 years in the Healthcare and Life Sciences Practice of Arthur D. Little. Eric holds two master’s degrees in pharmacology and Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.
My organisation
Sector: Chemicals, Pharmaceuticals and Lifesciences
About PDC*line Pharma
Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC_line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells (PDC_line). PDC_line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC_line Pharma focuses on the development of PDC_lung01, a candidate for Non-Small-Cell Lung Cancer (NSCLC) currently in phase I/II trials, and PDC_neo with neoantigens in preclinical development. The company has a staff of 42, with an experienced management team. It has raised more than €62M in equity and non-dilutive funding. In March 2019, PDC_line Pharma granted an exclusive license to the LG Chem Life Sciences company in South Korea and an exclusive option in other Asian countries, for the development and commercialization of the PDC_lung01 cancer vaccine for lung cancer. The total deal is worth $123M, plus tiered royalties on net sales in Asia.
Skills
- entrepreneuship
- biotechnology
- Fund raising
- deal making
- start-up development